Skip to content

Evaluation of nifedipine administration on embyro transfer success rate, a Randomized Clinical Trial

Evaluation of nifedipine administration on embyro transfer success rate, a Randomized Clinical Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201129049532N1
Enrollment
98
Registered
2021-11-21
Start date
2020-03-16
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility. Female infertility

Interventions

Intervention group: 18 - 40 year-old women with primary or secondary infertility, candidate for embryo transfer.

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Women aged 18-40 with primary or secondary infertility fresh or frozen embryo transfer good embryo quality(based on defined criteria) transfer of 3 embryo of two days age

Exclusion criteria

Exclusion criteria: Blood pressure less than 100/60mmHg Body mass index > 38 kg/m2 Abnormal uterine cavity(congenital or acquired) Nifedipine contraindications(history of severe allergic reaction, porphyria, severe heart failure) Recurrent implantation failure History of recurrent abortion

Design outcomes

Primary

MeasureTime frame
Clinical Pregnancy. Timepoint: Before intervention and 3 weeks after intervention. Method of measurement: Transvaginal ultrasound and serum Bhcg.

Secondary

MeasureTime frame
Live birth, multiple gestation, abortion. Timepoint: 3 weeks after intervention, 9 months after intervention if primaryboutcome occured. Method of measurement: Transvaginal ultrasound, successful delivery.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSolmaz Hedayat MD

Iran University of Medical Sciences

Solmaz.hedayat@yahoo.con0098 21 5025966

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026